MIDOR- Molecular Imaging for Differential diagnosis of Oncocytoma from Renal Cell Carcioma
| Reference number | |
| Coordinator | Karolinska Institutet - Institutionen för klinisk vetenskap, intervention och teknik |
| Funding from Vinnova | SEK 1 898 665 |
| Project duration | July 2015 - June 2017 |
| Status | Completed |
Important results from the project
The purpose of our project was to evaluate whether a molecular imaging with 99mTc Sestamibi SPECT/CT and quantitative analysis with SUV-SPECT could non-invasively reliably differentiate between benign tumor, namely Oncocytomas and Renal Cell Carcinoma (RCC). Our study intended to deliver tool for a reliable pre-operative differential diagnosis of Oncocytomas.
Expected long term effects
Fifty-six patients were examined with 99m Tc-Sestamibi SPECT/CT for the differentiation of Oncocytomas from RCC. Qualitative evaluation of first 27 patients with 31 lesions was performed and 12 oncocytomas were detected. Eleven of 12 oncocytomas (91,6%) displayed positive uptake of 99mTc-Sestamibi, while 11 of 12 RCC were Sestamibi-negative. A manuscript was published https://ejnmmires.springeropen.com/articles/10.1186/s13550-017-0278-z .
Approach and implementation
In the next step a reliability of new soft ware SUV SPECT® was tested for intra- and interobserver variability by two readers. Statistical evaluation of data are under processing. After that, the quantitative analysis delivered by application of SUV SPECT® will be performed with comparison to histopathological diagnosis according to study protocol. A cut-off level of Sestamibi uptake calculated from quantitative analysis will be integrated in the diagnostic algorithm for decision making.